Tesi and Debiopharm in $10m series-B for BC Platforms
Finnish VC investor Tesi and Swiss biopharmaceutical group Debiopharm have invested in a $10m series-B funding round for Basel-based genomic data management company BC Platforms.
More on DACH
Gyrus buys majority stake in Katalist Group
GP and Katalist's founders are planning bolt-ons for the food and pharma supply chain software firm
Unigestion gears up for Climate Impact Fund
GP in initial discussions with existing investors for first climate-focused fund
GP Profile: Ergon hones in on long-term trends, ESG agenda
The European mid-market sponsor is eyeing growing and resilient businesses with its EUR 800m Fund V
LGT Capital closes first dedicated impact fund on USD 550m
Crown Impact will make co-investments, as well as primary and secondary fund investments
Latest News
Gyrus buys majority stake in Katalist Group
GP and Katalist's founders are planning bolt-ons for the food and pharma supply chain software firm
Bain Capital, Nextalia to acquire Deltatre from Bruin Sports Capital
Italian sports technology provider first sale attempt was hampered by the onset of COVID-19 in early 2020
FirstAvenue appoints Chronias as capital solutions group head
Nick Chronias will lead the firm’s focus on private credit and private infrastructure secondaries
Riverside appoints Höppner as chief sustainability officer
Dörte Höppner joined the GP in 2017 and will be responsible for its ESG initiatives globally